Nirogacestat Hydrobromide Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as SPRINGWORKS. It is marketed under 1 brand name, including OGSIVEO. Available in 3 different strengths, such as EQ 50MG BASE, EQ 100MG BASE, EQ 150MG BASE, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"118238","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"dfdba8145d3c4a1cbb02","publication_number":"US7795447B2","cleaned_patent_number":"7795447","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-08-18","publication_date":"2010-09-14","legal_status":"Granted"} US7795447B2 Molecular 14 Sep, 2010 Granted 18 Aug, 2025
{"application_id":"118278","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"dfdba8145d3c4a1cbb02","publication_number":"US7342118B2","cleaned_patent_number":"7342118","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-08-18","publication_date":"2008-03-11","legal_status":"Granted"} US7342118B2 Molecular 11 Mar, 2008 Granted 18 Aug, 2025
{"application_id":"118279","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"dfdba8145d3c4a1cbb02","publication_number":"US7951958B2","cleaned_patent_number":"7951958","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-03-11","publication_date":"2011-05-31","legal_status":"Granted"} US7951958B2 Molecular 31 May, 2011 Granted 11 Mar, 2026
{"application_id":"120041","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11820748B2","cleaned_patent_number":"11820748","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2023-11-21","legal_status":"Granted"} US11820748B2 Formulation 21 Nov, 2023 Granted 09 Aug, 2039
{"application_id":"120033","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US10590087B1","cleaned_patent_number":"10590087","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2020-03-17","legal_status":"Granted"} US10590087B2 Molecular 17 Mar, 2020 Granted 09 Aug, 2039
{"application_id":"120034","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US10710966B1","cleaned_patent_number":"10710966","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2020-07-14","legal_status":"Granted"} US10710966B2 Molecular 14 Jul, 2020 Granted 09 Aug, 2039
{"application_id":"118213","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US10941118B2","cleaned_patent_number":"10941118","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2021-03-09","legal_status":"Patented case"} US10941118B2 Molecular 09 Mar, 2021 Patented case 09 Aug, 2039
{"application_id":"118223","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11845732B2","cleaned_patent_number":"11845732","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2023-12-19","legal_status":"Patented case"} US11845732B2 Molecular 19 Dec, 2023 Patented case 09 Aug, 2039
{"application_id":"120030","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11884634B2","cleaned_patent_number":"11884634","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2024-01-30","legal_status":"Granted"} US11884634B2 Formulation 30 Jan, 2024 Granted 09 Aug, 2039
{"application_id":"118227","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11884635B2","cleaned_patent_number":"11884635","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2024-01-30","legal_status":"Granted"} US11884635B2 Formulation 30 Jan, 2024 Granted 09 Aug, 2039
{"application_id":"121495","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11905255B1","cleaned_patent_number":"11905255","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2024-02-20","legal_status":"Granted"} US11905255B2 Formulation 20 Feb, 2024 Granted 09 Aug, 2039
{"application_id":"123206","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US12116347B2","cleaned_patent_number":"12116347","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2024-10-15","legal_status":"Granted"} US12116347B2 Formulation 15 Oct, 2024 Granted 09 Aug, 2039
{"application_id":"140930","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US2023406827A1","cleaned_patent_number":"12297177","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-09","publication_date":"2025-05-13","legal_status":"Granted"} US12297177B2 Formulation 13 May, 2025 Granted 09 Aug, 2039
{"application_id":"138535","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"","publication_number":"US12110277B2","cleaned_patent_number":"12110277","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-07-08","publication_date":"2024-10-08","legal_status":"Granted"} US12110277B2 Formulation 08 Oct, 2024 Granted 08 Jul, 2042
{"application_id":"118214","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11504354B1","cleaned_patent_number":"11504354","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-07-08","publication_date":"2022-11-22","legal_status":"Granted"} US11504354B2 Formulation 22 Nov, 2022 Granted 08 Jul, 2042
{"application_id":"164483","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"","publication_number":"US12247012B2","cleaned_patent_number":"12247012","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-07-08","publication_date":"2025-03-11","legal_status":"Granted"} US12247012B2 Formulation 11 Mar, 2025 Granted 08 Jul, 2042
{"application_id":"164484","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"","publication_number":"US12234210B2","cleaned_patent_number":"12234210","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-07-08","publication_date":"2025-02-25","legal_status":"Granted"} US12234210B2 Formulation 25 Feb, 2025 Granted 08 Jul, 2042
{"application_id":"120038","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11612588B1","cleaned_patent_number":"11612588","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-07-08","publication_date":"2023-03-28","legal_status":"Granted"} US11612588B2 Formulation 28 Mar, 2023 Granted 08 Jul, 2042
{"application_id":"118196","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11807611B2","cleaned_patent_number":"11807611","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-09-08","publication_date":"2023-11-07","legal_status":"Granted"} US11807611B2 Formulation 07 Nov, 2023 Granted 08 Sep, 2042
{"application_id":"118224","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11844780B2","cleaned_patent_number":"11844780","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-09-08","publication_date":"2023-12-19","legal_status":"Granted"} US11844780B2 Formulation 19 Dec, 2023 Granted 08 Sep, 2042
{"application_id":"123205","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US12036207B2","cleaned_patent_number":"12036207","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-07-16","legal_status":"Granted"} US12036207B2 16 Jul, 2024 Granted 19 May, 2043
{"application_id":"121912","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US12011434B2","cleaned_patent_number":"12011434","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-06-18","legal_status":"Granted"} US12011434B2 18 Jun, 2024 Granted 19 May, 2043
{"application_id":"121494","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11957662B2","cleaned_patent_number":"11957662","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-04-16","legal_status":"Granted"} US11957662B2 16 Apr, 2024 Granted 19 May, 2043
{"application_id":"124146","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US12138246B2","cleaned_patent_number":"12138246","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-11-12","legal_status":"Granted"} US12138246B2 12 Nov, 2024 Granted 19 May, 2043
{"application_id":"120350","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11925619B2","cleaned_patent_number":"11925619","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-03-12","legal_status":"Granted"} US11925619B2 12 Mar, 2024 Granted 19 May, 2043
{"application_id":"121631","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11951096B2","cleaned_patent_number":"11951096","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-04-09","legal_status":"Granted"} US11951096B2 09 Apr, 2024 Granted 19 May, 2043
{"application_id":"118225","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11872211B2","cleaned_patent_number":"11872211","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-01-16","legal_status":"Patented case"} US11872211B2 16 Jan, 2024 Patented case 19 May, 2043
{"application_id":"121493","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11938116B2","cleaned_patent_number":"11938116","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-03-26","legal_status":"Granted"} US11938116B2 26 Mar, 2024 Granted 19 May, 2043
{"application_id":"121569","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US11925620B1","cleaned_patent_number":"11925620","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-03-12","legal_status":"Granted"} US11925620B2 12 Mar, 2024 Granted 19 May, 2043
{"application_id":"123255","ingredient":"NIROGACESTAT HYDROBROMIDE","trade_name":"OGSIVEO","family_id":"4edd9714d11c432b9040","publication_number":"US12011435B2","cleaned_patent_number":"12011435","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-05-19","publication_date":"2024-06-18","legal_status":"Granted"} US12011435B2 18 Jun, 2024 Granted 19 May, 2043

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Nirogacestat Hydrobromide

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.